| 6.71 -0.38 (-5.36%) | 01-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.3  |
1-year : | 9.7 |
| Resists | First : | 7.11 |
Second : | 8.3 |
| Pivot price | 6.32 |
|||
| Supports | First : | 5.8 |
Second : | 5 |
| MAs | MA(5) : | 6.65 |
MA(20) : | 6.15 |
| MA(100) : | 5.51 |
MA(250) : | 6.41 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 80.3 |
D(3) : | 76.5 |
| RSI | RSI(14): 60.1 |
|||
| 52-week | High : | 10.5 | Low : | 4.4 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BOLT ] has closed below upper band by 26.3%. Bollinger Bands are 42.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 7.13 - 7.16 | 7.16 - 7.19 |
| Low: | 6.58 - 6.62 | 6.62 - 6.66 |
| Close: | 6.65 - 6.72 | 6.72 - 6.77 |
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
Wed, 21 Jan 2026
Bolt (Fastener) Market Covering Prime Factors and Competitive - openPR.com
Thu, 13 Nov 2025
Bolt Reports Q3 2025 Financial Results And Highlights Progress Across Oncology Pipeline - Nasdaq
Wed, 12 Nov 2025
Bolt Biotherapeutics Reports Improved Financial Performance - TipRanks
Wed, 12 Nov 2025
Bolt Biotherapeutics (NASDAQ: BOLT) reports $38.8M cash, runway into 2027 - Stock Titan
Tue, 04 Nov 2025
Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Mon, 20 Oct 2025
Bolt Biotherapeutics stock initiated with Buy rating at H.C. Wainwright - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 6.6 (%) |
| Held by Institutions | 40.2 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 1 (K) |
| EPS | -22.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 16.71 |
| Profit Margin | 0 % |
| Operating Margin | -355.2 % |
| Return on Assets (ttm) | -32.1 % |
| Return on Equity (ttm) | -82 % |
| Qtrly Rev. Growth | 90 % |
| Gross Profit (p.s.) | -15.67 |
| Sales Per Share | 2.7 |
| EBITDA (p.s.) | -22.52 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -47 (M) |
| Levered Free Cash Flow | -32 (M) |
| PE Ratio | -0.31 |
| PEG Ratio | 0 |
| Price to Book value | 0.4 |
| Price to Sales | 2.47 |
| Price to Cash Flow | -0.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|